•C-reactive Proteins
•Others (galectin-3, myeloperoxidase, homocysteine, H-FABP, and ischemia-modified
albumin)
By product type:
•Instruments
•Chemiluminescence
•Immunofluorescence
•Immunochromatography
•ELISA
•Reagents and kits
By application:
•Acute Coronary Syndrome (ACS)
•Myocardial Infraction (MI)
•Cardiac Heart Failure
•Others
By testing type:
•Laboratory testing
•Pont-of-care testing
By end user:
•Hospitals
•Diagnostic Laboratory
•Home care setting
Major acquisitions are expected to drive growth of the cardiac marker testing devices market
In 2017, U.S. Federal Trade Commission (FTC) allowed US$ 5.3 billion of acquisition of Alere’s
point-of-care cardiac marker testing business to Abbott Laboratories. The deal between Abbott
Laboratories and Alere created the world’s largest point-of-care testing business, which significantly
strengthen and grow Abbott’s diagnostic presence in cardiac marker testing devices market.
Moreover, in 2017, FTC approved the deal of Alere’s Triage B-type Naturietic Peptide (BNP) assay
business and Triage MeterPro toxicology and cardiovascular business with Quidel Corporation. The
acquisition of Alere’s point-of-care cardiac marker testing business is expected to improve Quidel’s
portfolio of rapid diagnostic testing solutions.
Key players in the cardiac marker testing devices market
Some of the key players operating in the global cardiac marker testing devices market are Bio-Rad
Laboratories, Inc., Siemens Medical Solutions USA, Inc., Randox Laboratories Ltd., Abbott
Laboratories, Becton, Dickinson and Company, Helomics Corp., LSI Medience Corporation,
F.Hoffmann-La Roche Ltd., Enzo Biochem Inc., Ortho Clinical Diagnostics, Danaher Corporation,
and bioMerieux SA.